Literature DB >> 2568375

Pentagastrin stimulation of calcitonin in pheochromocytoma does not always indicate multiple endocrine neoplasia type II.

M D Hein1, J M Monchik, I M Jackson.   

Abstract

The diagnosis of pheochromocytoma in a 48-year-old man was confirmed by elevated catecholamine secretion and a left adrenal mass on computerized tomography. Because of a plausible family history for Multiple Endocrine Neoplasia Type II, a calcitonin level was determined which was elevated, and pentagastrin stimulation caused a 235% increase. These findings normalized following surgical removal of the single adrenal tumor. It is concluded that pentagastrin stimulation of calcitonin is not necessarily diagnostic of medullary thyroid carcinoma, and such a response in a patient presenting with pheochromocytoma may not indicate underlying Multiple Endocrine Neoplasia Type II.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568375     DOI: 10.1007/BF03349981

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  9 in total

1.  Letter: Hypersecretion of calcitonin in neoplastic conditions.

Authors:  G Milhaud; C Calmette; J Taboulet; A Julienne; M S Moukhtar
Journal:  Lancet       Date:  1974-03-16       Impact factor: 79.321

2.  Ectopic secretion of calcitonin.

Authors:  H Mulder; W H Hackeng
Journal:  Acta Med Scand       Date:  1978

3.  Immunoreactive calcitonin in pheochromocytomas.

Authors:  R S Weinstein; L F Ide
Journal:  Proc Soc Exp Biol Med       Date:  1980-11

4.  Dilemmas in the early diagnosis and treatment of multiple endocrine adenomatosis, type II.

Authors:  D T Freier; N W Thompson; J C Sisson; R H Nishiyama; J E Freitas
Journal:  Surgery       Date:  1977-09       Impact factor: 3.982

5.  Immunoreactive calcitonin in catecholamine storage vesicles of human pheochromocytoma.

Authors:  D T O'Connor; R P Frigon; L J Deftos
Journal:  J Clin Endocrinol Metab       Date:  1983-03       Impact factor: 5.958

6.  Immunohistochemical study of pheochromocytomas. An investigation of methionine-enkephalin, vasoactive intestinal peptide, somatostatin, corticotropin, beta-endorphin, and calcitonin in 16 tumors.

Authors:  J Hassoun; G Monges; P Giraud; J F Henry; C Charpin; H Payan; M Toga
Journal:  Am J Pathol       Date:  1984-01       Impact factor: 4.307

7.  The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience.

Authors:  R F Gagel; A H Tashjian; T Cummings; N Papathanasopoulos; M M Kaplan; R A DeLellis; H J Wolfe; S Reichlin
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

8.  Pheochromocytoma associated with hypercalcemia and ectopic secretion of calcitonin.

Authors:  H Heath; A J Edis
Journal:  Ann Intern Med       Date:  1979-08       Impact factor: 25.391

9.  Bilateral occurrence of pheochromocytoma in patients with the multiple endocrine neoplasia syndrome type 2A (Sipple's syndrome).

Authors:  K J Lips; J Van der Sluys Veer; A Struyvenberg; A Alleman; J R Leo; P Wittebol; W H Minder; C J Kooiker; R A Geerdink; P F Van Waes; W H Hackeng
Journal:  Am J Med       Date:  1981-05       Impact factor: 4.965

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.